NCT00165672View on ClinicalTrials.gov

A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

October 31, 2005

Study Completion Date

October 31, 2005

Conditions
Non-erosive Gastroesophageal Reflux Disease
Interventions
DRUG

RABEPRAZOLE SODIUM

rabeprazole sodium 5 mg: once daily orally for 4 weeks

DRUG

RABEPRAZOLE SODIUM

rabeprazole sodium 10 mg: once daily orally for 4 weeks

Trial Locations (13)

467-0001

Nagoya

810-0001

Fukuoka

811-0213

Fukuoka

824-0026

Yukuhashi

734-0037

Hiroshima

530-0012

Osaka

545-0051

Osaka

849-0937

Saga

520-2121

Ōtsu

693-0021

Izumo

113-0022

Bunkyo-ku

162-0052

Shinjuku-ku

755-0046

Ube

All Listed Sponsors
collaborator

Eisai Limited

INDUSTRY

lead

Eisai Inc.

INDUSTRY

NCT00165672 - A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease | Biotech Hunter | Biotech Hunter